INmune Bio’s (INMB) treatment of epidermolysis bullosa received FDA orphan designation, according to a post on the agency’s site.Don't Miss Our ...

StockNews.com lowered shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a hold rating to a sell rating in a research note published on Thursday morning. ABEO has been the subject of a ...

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO ...

City Therapeutics appoints Andrew Orth as CEO, leveraging his expertise in RNA and gene therapies as the company advances its ...

Ironwood Pharmaceuticals Inc. Cl A 1.10% $724.93M ...

After hours: January 10 at 4:08:24 PM EST Loading Chart for ABEO ...

In particular, the scientists believe that the atlas could be important for the study of genes that cause congenital hair and skin disorders like epidermolysis bullosa (EB), which causes severe ...

Adhesive products are selected based on the intended purpose, as well as the anatomic location the adhesive will be attached. An important patient consideration is the type of device being secured ...

City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the appointment of Andrew "Andy" Orth as chief executive officer and ...